Interleukin-1-receptor antagonist in type 2 diabetes mellitus
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The expression of interleukin-1-receptor antagonist is reduced in pancreatic islets of patients with type 2 diabetes mellitus, and high glucose concentrations induce the production of interleukin-1beta in human pancreatic beta cells, leading to impaired insulin secretion, decreased cell proliferation, and apoptosis. METHODS: In this double-blind, parallel-group trial involving 70 patients with type 2 diabetes, we randomly assigned 34 patients to receive 100 mg of anakinra (a recombinant human interleukin-1-receptor antagonist) subcutaneously once daily for 13 weeks and 36 patients to receive placebo. At baseline and at 13 weeks, all patients underwent an oral glucose-tolerance test, followed by an intravenous bolus of 0.3 g of glucose per kilogram of body weight, 0.5 mg of glucagon, and 5 g of arginine. In addition, 35 patients underwent a hyperinsulinemic-euglycemic clamp study. The primary end point was a change in the level of glycated hemoglobin, and secondary end points were changes in beta-cell function, insulin sensitivity, and inflammatory markers. RESULTS: At 13 weeks, in the anakinra group, the glycated hemoglobin level was 0.46 percentage point lower than in the placebo group (P=0.03); C-peptide secretion was enhanced (P=0.05), and there were reductions in the ratio of proinsulin to insulin (P=0.005) and in levels of interleukin-6 (P<0.001) and C-reactive protein (P=0.002). Insulin resistance, insulin-regulated gene expression in skeletal muscle, serum adipokine levels, and the body-mass index were similar in the two study groups. Symptomatic hypoglycemia was not observed, and there were no apparent drug-related serious adverse events. CONCLUSIONS: The blockade of interleukin-1 with anakinra improved glycemia and beta-cell secretory function and reduced markers of systemic inflammation. (ClinicalTrials.gov number, NCT00303394 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recently, early interventions with insulin therapy in newly diagnosed T2D ( 83 ), with targeted anti-inflammatory therapy using an IL-1β antagonist ( 84 ), and with GLP-1 receptor agonists ( 85 ) have demonstrated that β-cell dysfunction can be reversed temporarily.”
From β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment (2014) · cites this paper as [84]
In the citing paper
“improved glucose control required fewer glucose-lowering agents, including insulin”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [135]
In the citing paper
“a greater proportion of participants achieved a HbA1c <7%135”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [135]
In the citing paper
“A benefit for anakinra was also shown in a small, randomized trial of 70 patients with type 2 diabetes109.”
From Sterile inflammation: sensing and reacting to damage (2010) · cites this paper as [109]
In the citing paper
“However, the clinical study was still small and was not designed to determine optimal dosing, duration of use or long-term outcomes in disease control.”
From Sterile inflammation: sensing and reacting to damage (2010) · cites this paper as [109]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Mootha, V. K., Lindgren, C. M., Eriksson, K.-F., Subramanian, A., Sihag, S., Lehar, J., Puigserver, P., Carlsson, E., Ridderstråle, M., Laurila, E., et al. (2003) · Nature Genetics · doi:10.1038/ng1180 · Cited by 10,197
Use and Abuse of HOMA Modeling
Wallace, T. M., Levy, J. C., & Matthews, D. R. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1487 · Cited by 5,114
Biologic basis for interleukin-1 in disease.
Dinarello, C. (1996) · Blood · doi:10.1182/blood.v87.6.2095.bloodjournal8762095 · Cited by 4,344
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
The Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM
DeFronzo, R. A. (1988) · Diabetes · doi:10.2337/diab.37.6.667 · Cited by 2,456
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets
Maedler, K., Sergeev, P., Ris, F., Oberholzer, J., Joller-Jemelka, H. I., Spinas, G. A., Kaiser, N., Halban, P. A., & Donath, M. Y. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92172 · Cited by 1,114
Self-citationGlucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets
Maedler, K., Sergeev, P., Ris, F., Oberholzer, J., Joller-Jemelka, H. I., Spinas, G. A., Kaiser, N., Halban, P. A., & Donath, M. Y. (2002) · Journal of Clinical Investigation · doi:10.1172/jci200215318 · Cited by 1,005
Self-citationNeonatal-Onset Multisystem Inflammatory Disease Responsive to Interleukin-1β Inhibition
Goldbach-Mansky, R., Dailey, N. J., Canna, S. W., Gelabert, A., Jones, J., Rubin, B. I., Kim, H. J., Brewer, C., Zalewski, C., Wiggs, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055137 · Cited by 930
Diagnosis and Classification of Diabetes Mellitus
American Diabetes Association (2006) · Diabetes Care · doi:10.2337/diacare.29.s1.06.s43 · Cited by 924
Cited by
Items 201–300 of 1,001
Ehses, J. A., Meier, D. T., Wueest, S., Rytka, J., Boller, S., Wielinga, P. Y., Schraenen, A., Lemaire, K., Debray, S., Van Lommel, L., et al. (2010) · Diabetologia · doi:10.1007/s00125-010-1747-3 · Cited by 222
“Indeed, clinical data have shown improved insulin resistance after treatment of type 2 diabetes patients with salicylate (via inhibition of nuclear factor κ B[ NF-κB]) [4, 5], and improved beta cell insulin secretion in patients after treatment with the IL-1 receptor antagonist (IL-1Ra) [ 6 ].”
BackgroundSelf-citationβ-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment
Halban, P. A., Polonsky, K. S., Bowden, D. W., Hawkins, M. A., Ling, C., Mather, K. J., Powers, A. C., Rhodes, C. J., Sussel, L., & Weir, G. C. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1425 · Cited by 222
Inflammasomes and autoimmunity
Shaw, P. J., McDermott, M. F., & Kanneganti, T.-D. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.11.001 · Cited by 234
Blockade of interleukin 1 in type 1 diabetes mellitus
Mandrup-Poulsen, T., Pickersgill, L., & Donath, M. Y. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.271 · Cited by 237
“On the basis of this rationale, two studies have assessed the effects of the human recombinant IL-1r”
BackgroundSelf-citationRütti, S., Ehses, J. A., Sibler, R. A., Prazak, R., Rohrer, L., Georgopoulos, S., Meier, D. T., Niclauss, N., Berney, T., Donath, M. Y., et al. (2009) · Endocrinology · doi:10.1210/en.2009-0252 · Cited by 237
Self-citationType 1 diabetes: translating mechanistic observations into effective clinical outcomes
Herold, K. C., Vignali, D. A. A., Cooke, A., & Bluestone, J. A. (2013) · Nature Reviews Immunology · doi:10.1038/nri3422 · Cited by 237
Chung, C. P., Oeser, A., Solus, J. F., Gebretsadik, T., Shintani, A., Avalos, I., Sokka, T., Raggi, P., Pincus, T., & Stein, C. M. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23600 · Cited by 230
Cytokine production by islets in health and diabetes: cellular origin, regulation and function
Donath, M. Y., Böni-Schnetzler, M., Ellingsgaard, H., Halban, P. A., & Ehses, J. A. (2010) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2009.12.010 · Cited by 227
Self-citationAdipokines: masterminds of metabolic inflammation
Tilg, H., Ianiro, G., Gasbarrini, A., & Adolph, T. E. (2025) · Nature Reviews Immunology · doi:10.1038/s41577-024-01103-8 · Cited by 192
The role of hepatic fat accumulation in pathogenesis of non-alcoholic fatty liver disease (NAFLD)
Liu, Q., Bengmark, S., & Qu, S. (2010) · Lipids in Health and Disease · doi:10.1186/1476-511x-9-42 · Cited by 229
Igoillo-Esteve, M., Marselli, L., Cunha, D. A., Ladrière, L., Ortis, F., Grieco, F. A., Dotta, F., Weir, G. C., Marchetti, P., Eizirik, D. L., et al. (2010) · Diabetologia · doi:10.1007/s00125-010-1707-y · Cited by 227
“Moreover, IL-1ra therapy is under evaluation for the treatment of type 2 diabetes [34, 35 ], based on studies suggesting that high-glucose-induced IL-1β secretion by beta cells causes beta cell dysfunction and death [21].”
BackgroundObesity-associated low-grade inflammation in type 2 diabetes mellitus: causes and consequences.
van Greevenbroek, M. M. J., Schalkwijk, C., & Stehouwer, C. D. A. (2013) · PubMed · Cited by 284
How Does Type 1 Diabetes Develop?
Atkinson, M. A., Bluestone, J. A., Eisenbarth, G. S., Hebrok, M., Herold, K. C., Accili, D., Pietropaolo, M., Arvan, P. R., Von Herrath, M., Markel, D. S., et al. (2011) · Diabetes · doi:10.2337/db10-1797 · Cited by 232
Westwell-Roper, C. Y., Ehses, J. A., & Verchere, C. B. (2014) · Diabetes · doi:10.2337/db13-0863 · Cited by 224
Self-citationVarra, F.-N., Varras, M., Varra, V.-K., & Theodosis‑Nobelos, P. (2024) · Molecular Medicine Reports · doi:10.3892/mmr.2024.13219 · Cited by 190
Fatty Acids and NLRP3 Inflammasome–Mediated Inflammation in Metabolic Tissues
Ralston, J. C., Lyons, C. L., Kennedy, E. B., Kirwan, A. M., & Roche, H. M. (2017) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071816-064836 · Cited by 225
Biosynthesis, structure, and folding of the insulin precursor protein
Liu, M., Weiss, M. A., Arunagiri, A., Yong, J., Rege, N., Sun, J., Haataja, L., Kaufman, R. J., & Arvan, P. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13378 · Cited by 215
Schultz, O., Oberhauser, F., Saech, J., Rubbert-Roth, A., Hahn, M., Krone, W., & Laudes, M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0014328 · Cited by 225
Tuleta, I., & Frangogiannis, N. G. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.166044 · Cited by 208
“It should be emphasized that pro-inflammatory cytokine signaling has also been implicated in the pathogenesis of metabolic dysfunction in both type 1 and type 2 diabetes [76],[77].”
BackgroundInterleukin-1β and the Autoinflammatory Diseases
Dinarello, C. A. (2009) · New England Journal of Medicine · doi:10.1056/nejme0811014 · Cited by 226
Biologics for targeting inflammatory cytokines, clinical uses, and limitations
Rider, P., Carmi, Y., & Cohen, I. (2016) · International Journal of Cell Biology · doi:10.1155/2016/9259646 · Cited by 226
Innate and adaptive immune responses to cell death
Rock, K. L., Lai, J., & Kono, H. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01040.x · Cited by 221
Interleukin-1 (IL-1) family of cytokines: Role in Type 2 Diabetes
Banerjee, M., & Saxena, M. (2012) · Clinica Chimica Acta · doi:10.1016/j.cca.2012.03.021 · Cited by 224
The role of FOXO1 in β-cell failure and type 2 diabetes mellitus
Kitamura, T. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.157 · Cited by 221
Islet inflammation in type 2 diabetes
Böni-Schnetzler, M., & Meier, D. T. (2019) · Seminars in Immunopathology · doi:10.1007/s00281-019-00745-4 · Cited by 207
IL-37 protects against obesity-induced inflammation and insulin resistance
Ballak, D. B., van Diepen, J. A., Moschen, A. R., Jansen, H. J., Hijmans, A., Groenhof, G.-J., Leenders, F., Bufler, P., Boekschoten, M. V., Müller, M., et al. (2014) · Nature Communications · doi:10.1038/ncomms5711 · Cited by 223
Cytokines and β-Cell Biology: from Concept to Clinical Translation
Donath, M. Y., Størling, J., Berchtold, L. A., Billestrup, N., & Mandrup-Poulsen, T. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0033 · Cited by 222
Self-citationUpdated insights into the molecular networks for NLRP3 inflammasome activation
Paik, S., Kim, J. K., Shin, H. J., Park, E.-J., Kim, I. S., & Jo, E.-K. (2025) · Cellular & Molecular Immunology · doi:10.1038/s41423-025-01284-9 · Cited by 180
Sibley, C. H., Plass, N., Snow, J., Wiggs, E. A., Brewer, C. C., King, K. A., Zalewski, C., Kim, H. J., Bishop, R., Hill, S., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34409 · Cited by 220
Gene Expression in Peripheral Blood Mononuclear Cells from Children with Diabetes
Kaizer, E. C., Glaser, C. L., Chaussabel, D., Banchereau, J., Pascual, V., & White, P. C. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0979 · Cited by 219
Role of C-Reactive Protein in Diabetic Inflammation
Stanimirovic, J., Radovanovic, J., Banjac, K., Obradovic, M., Essack, M., Zafirovic, S., Gluvic, Z., Gojobori, T., & Isenovic, E. R. (2022) · Mediators of Inflammation · doi:10.1155/2022/3706508 · Cited by 192
on behalf of the Heinz Nixdorf Recall Investigator Group, Weinmayr, G., Hennig, F., Fuks, K., Nonnemacher, M., Jakobs, H., Möhlenkamp, S., Erbel, R., Jöckel, K.-H., Hoffmann, B., et al. (2015) · Environmental Health · doi:10.1186/s12940-015-0031-x · Cited by 206
Gehrke, N., & Schattenberg, J. M. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.02.020 · Cited by 209
NOD-like receptors and the innate immune system: Coping with danger, damage and death
Kersse, K., Bertrand, M. J. M., Lamkanfi, M., & Vandenabeele, P. (2011) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2011.09.003 · Cited by 201
“Moreover, therapy with the IL-1b antagonist Anakinra (Kineret, Amgen) has proven its effectiveness in multiple CAPS cases, gout and type 2 diabetes [139,140,155–157].”
BackgroundHerder, C., Brunner, E. J., Rathmann, W., Strassburger, K., Tabák, A. G., Schloot, N. C., & Witte, D. R. (2009) · Diabetes Care · doi:10.2337/dc08-1161 · Cited by 206
The Role of Inflammation in β-cell Dedifferentiation
Nordmann, T. M., Dror, E., Schulze, F., Traub, S., Berishvili, E., Barbieux, C., Böni-Schnetzler, M., & Donath, M. Y. (2017) · Scientific Reports · doi:10.1038/s41598-017-06731-w · Cited by 204
Self-citationRecent advances in obesity-induced inflammation and insulin resistance
Tateya, S., Kim, F., & Tamori, Y. (2013) · Frontiers in Endocrinology · doi:10.3389/fendo.2013.00093 · Cited by 211
Clinical Relevance of Adipokines
Blüher, M. (2012) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2012.36.5.317 · Cited by 200
Hypothalamic Inflammation in the Control of Metabolic Function
Valdearcos, M., Xu, A. W., & Koliwad, S. K. (2015) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021014-071656 · Cited by 201
Chakraborty, A., Tannenbaum, S., Rordorf, C., Lowe, P. J., Floch, D., Gram, H., & Roy, S. (2012) · Clinical Pharmacokinetics · doi:10.2165/11599820-000000000-00000 · Cited by 199
Innate immunity, insulin resistance and type 2 diabetes
Fernández-Real, J. M., & Pickup, J. C. (2008) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2007.10.004 · Cited by 207
Vujkovic, M., Ramdas, S., Lorenz, K. M., Guo, X., Darlay, R., Cordell, H. J., He, J., Gindin, Y., Chung, C., Myers, R. P., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01078-z · Cited by 205
Molecular links between endocrine, nervous and immune system during chronic stress
Zefferino, R., Di Gioia, S., & Conese, M. (2021) · Brain and Behavior · doi:10.1002/brb3.1960 · Cited by 204
“In addition, long-term sleep deprivation is linked to pathologies as metabolic syndrome, (Hristova et al., 2006; Jager et al., 2007; Larsen et al., 2007) chronic inflammation (Frey et al., 2007; Hu et al., 2003), and cardiovascular disease (Yndestad et al., 2007).”
BackgroundMechanisms of disease: inflammasome activation and the development of type 2 diabetes
Grant, R. W., & Dixit, V. D. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00050 · Cited by 203
“Larsen et al. conducted a doubleblind, parallel-group trial in which anakinra (n = 34) or placebo (n = 33) was administered subcutaneously once/day for 13 weeks (Larsen et al., 2007).”
BackgroundMethodInfluentialVitamin D and diabetes: Its importance for beta cell and immune function
Wolden-Kirk, H., Overbergh, L., Christesen, H. T., Brusgaard, K., & Mathieu, C. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.08.016 · Cited by 200
The mechanism of NLRP3 inflammasome activation and its pharmacological inhibitors
Zhan, X., Li, Q., Xu, G., Xiao, X., & Bai, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1109938 · Cited by 181
“IL-1b is reported to inhibit insulin signaling (92–94); randomized clinical trials shows that blocking IL-1b signaling (using recombinant human IL-1 receptor antagonist) is effective in type 2 diabetes (94).”
BackgroundVolarevic, V., Al-Qahtani, A., Arsenijevic, N., Pajovic, S., & Lukic, M. L. (2010) · Autoimmunity · doi:10.3109/08916930903305641 · Cited by 197
Sauter, N. S., Schulthess, F. T., Galasso, R., Castellani, L. W., & Maedler, K. (2008) · Endocrinology · doi:10.1210/en.2007-1059 · Cited by 198
“Results from a recent clinical study in patients with T2DM showed that IL-1Ra improved glycemic control and -cell function (36).”
BackgroundAlternative Pathways of IL-1 Activation, and Its Role in Health and Disease
Pyrillou, K., Burzynski, L. C., & Clarke, M. C. H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.613170 · Cited by 185
Metabolic inflammation: Connecting obesity and insulin resistance
Dali-Youcef, N., Mecili, M., Ricci, R., & Andrès, E. (2013) · Annals of Medicine · doi:10.3109/07853890.2012.705015 · Cited by 190
Lipid-induced pancreatic β-cell dysfunction: focus on in vivo studies
Giacca, A., Xiao, C., Oprescu, A. I., Carpentier, A. C., & Lewis, G. F. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00416.2010 · Cited by 196
“Treatment with IL-1R antagonist improved insulin sensitivity and -cell function in type 2 diabetic patients (51).”
BackgroundMcGillicuddy, F. C., Harford, K. A., Reynolds, C. M., Oliver, E., Claessens, M., Mills, K. H. G., & Roche, H. M. (2011) · Diabetes · doi:10.2337/db10-1278 · Cited by 199
Inflammation links excess fat to insulin resistance: the role of the interleukin‐1 family
Tack, C. J., Stienstra, R., Joosten, L. A. B., & Netea, M. G. (2012) · Immunological Reviews · doi:10.1111/j.1600-065x.2012.01145.x · Cited by 193
Mahdi, T., Hänzelmann, S., Salehi, A., Muhammed, S. J., Reinbothe, T. M., Tang, Y., Axelsson, A. S., Zhou, Y., Jing, X., Almgren, P., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.10.009 · Cited by 193
Roles of the NLRP3 inflammasome in the pathogenesis of diabetic nephropathy
Qiu, Y.-Y., & Tang, L.-Q. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.11.004 · Cited by 195
Lee, T., Yun, S., Jeong, J. H., & Jung, T. W. (2019) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2019.03.001 · Cited by 188
Innate sensors of pathogen and stress: Linking inflammation to obesity
Jin, C., & Flavell, R. A. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.06.022 · Cited by 196
Adipose Organ Development and Remodeling
Cinti, S. (2018) · Comprehensive Physiology · doi:10.1002/cphy.c170042 · Cited by 164
Yu, M., & Levine, S. J. (2011) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2011.02.001 · Cited by 190
“A randomized clinical trial of anakinra in type 2 diabetes mellitus showed improvements in hyperglycemia, b-cell secretory function and systemic inflammation [111].”
BackgroundWestwell-Roper, C., Dai, D. L., Soukhatcheva, G., Potter, K. J., van Rooijen, N., Ehses, J. A., & Verchere, C. B. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002854 · Cited by 190
Self-citationα1-Antitrypsin monotherapy induces immune tolerance during islet allograft transplantation in mice
Lewis, E. C., Mizrahi, M., Toledano, M., DeFelice, N., Wright, J. L., Churg, A., Shapiro, L., & Dinarello, C. A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807627105 · Cited by 188
Inflammatory cause of metabolic syndrome via brain stress and NF-κB
Cai, D., & Liu, T. (2012) · Aging · doi:10.18632/aging.100431 · Cited by 189
Regulatory T cells in obesity: the leptin connection
Matarese, G., Procaccini, C., De Rosa, V., Horvath, T. L., & La Cava, A. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.04.002 · Cited by 185
Targeting inflammation in diabetes: Newer therapeutic options
Agrawal, N. K. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i5.697 · Cited by 186
Pancreatic Beta Cell Death: Novel Potential Mechanisms in Diabetes Therapy
Rojas, J., Bermudez, V., Palmar, J., Martínez, M. S., Olivar, L. C., Nava, M., Tomey, D., Rojas, M., Salazar, J., Garicano, C., et al. (2018) · Journal of Diabetes Research · doi:10.1155/2018/9601801 · Cited by 175
UCP1 governs liver extracellular succinate and inflammatory pathogenesis
Mills, E. L., Harmon, C., Jedrychowski, M. P., Xiao, H., Garrity, R., Tran, N. V., Bradshaw, G. A., Fu, A., Szpyt, J., Reddy, A., et al. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00389-5 · Cited by 182
Moschen, A. R., Molnar, C., Enrich, B., Geiger, S., Ebenbichler, C. F., & Tilg, H. (2011) · Molecular Medicine · doi:10.2119/molmed.2010.00108 · Cited by 184
Inflammasomes: far beyond inflammation
Henao-Mejia, J., Elinav, E., Strowig, T., & Flavell, R. A. (2012) · Nature Immunology · doi:10.1038/ni.2257 · Cited by 183
Connecting Type 1 and Type 2 Diabetes through Innate Immunity
Odegaard, J. I., & Chawla, A. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a007724 · Cited by 186
Elimination of the NLRP3-ASC Inflammasome Protects against Chronic Obesity-Induced Pancreatic Damage
Youm, Y.-H., Adijiang, A., Vandanmagsar, B., Burk, D., Ravussin, A., & Dixit, V. D. (2011) · Endocrinology · doi:10.1210/en.2011-1326 · Cited by 174
Sloan-Lancaster, J., Abu-Raddad, E., Polzer, J., Miller, J. W., Scherer, J. C., De Gaetano, A., Berg, J. K., & Landschulz, W. H. (2013) · Diabetes Care · doi:10.2337/dc12-1835 · Cited by 184
WNT/β-Catenin Signaling Induces IL-1β Expression by Alveolar Epithelial Cells in Pulmonary Fibrosis
Aumiller, V., Balsara, N., Wilhelm, J., Günther, A., & Königshoff, M. (2013) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2012-0524oc · Cited by 181
Islet Transplantation for Brittle Type 1 Diabetes: The UIC Protocol
Gangemi, A., Salehi, P., Hatipoglu, B., Martellotto, J., Barbaro, B., Kuechle, J. B., Qi, M., Wang, Y., Pallan, P., Owens, C., et al. (2008) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2008.02234.x · Cited by 184
FoxO1 Links Insulin Resistance to Proinflammatory Cytokine IL-1β Production in Macrophages
Su, D., Coudriet, G. M., Hyun Kim, D., Lu, Y., Perdomo, G., Qu, S., Slusher, S., Tse, H. M., Piganelli, J., Giannoukakis, N., et al. (2009) · Diabetes · doi:10.2337/db09-0232 · Cited by 180
Inflammation: a culprit for vascular calcification in atherosclerosis and diabetes
Bessueille, L., & Magne, D. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-1876-4 · Cited by 172
How is inflammation initiated? Individual influences of IL-1, IL-18 and HMGB1
Keyel, P. A. (2014) · Cytokine · doi:10.1016/j.cyto.2014.03.007 · Cited by 176
Programmed Necrosis and Disease:We interrupt your regular programming to bring you necroinflammation
Kim, E. H., Wong, S.-W., & Martinez, J. (2019) · Cell Death & Differentiation · doi:10.1038/s41418-018-0179-3 · Cited by 177
Insulin Resistance in Patients with Chronic Kidney Disease
Liao, M.-T., Sung, C.-C., Hung, K.-C., Wu, C.-C., Lo, L., & Lu, K.-C. (2012) · Journal of Biomedicine and Biotechnology · doi:10.1155/2012/691369 · Cited by 165
Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies
Cavalli, G., & Dinarello, C. A. (2015) · Rheumatology · doi:10.1093/rheumatology/kev269 · Cited by 171
Lighting the fires within: the cell biology of autoinflammatory diseases
Park, H., Bourla, A. B., Kastner, D. L., Colbert, R. A., & Siegel, R. M. (2012) · Nature Reviews Immunology · doi:10.1038/nri3261 · Cited by 174
Inflammation during obesity is not all bad: evidence from animal and human studies
Ye, J., & McGuinness, O. P. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00266.2012 · Cited by 174
IL-1 family cytokines trigger sterile inflammatory disease
Lukens, J. R., Gross, J. M., & Kanneganti, T.-D. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00315 · Cited by 172
The IL-1 Pathway in Type 2 Diabetes and Cardiovascular Complications
Herder, C., Dalmas, E., Böni-Schnetzler, M., & Donath, M. Y. (2015) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2015.08.001 · Cited by 168
“T2D IL-1Ra (anakinra) Placebo controlled for 13 weeks HbA1c #, leukocytes #, CRP #, insulin secretion " Dose not adapted to body weight [20]”
BackgroundMethodSelf-citationUnsaturated fatty acids prevent activation of NLRP3 inflammasome in human monocytes/macrophages
L'homme, L., Esser, N., Riva, L., Scheen, A., Paquot, N., Piette, J., & Legrand-Poels, S. (2013) · Journal of Lipid Research · doi:10.1194/jlr.m037861 · Cited by 168
Inflammasomes and Metabolic Disease
Henao-Mejia, J., Elinav, E., Thaiss, C. A., & Flavell, R. A. (2014) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021113-170324 · Cited by 134
Therapeutic approaches targeting inflammation for diabetes and associated cardiovascular risk
Goldfine, A. B., & Shoelson, S. E. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88884 · Cited by 172
Hyperglycemia Activates Caspase-1 and TXNIP-Mediated IL-1β Transcription in Human Adipose Tissue
Koenen, T. B., Stienstra, R., van Tits, L. J., de Graaf, J., Stalenhoef, A. F. H., Joosten, L. A. B., Tack, C. J., & Netea, M. G. (2011) · Diabetes · doi:10.2337/db10-0266 · Cited by 172
Yazdi, A. S., & Ghoreschi, K. (2016) · Advances in Experimental Medicine and Biology · doi:10.1007/978-94-024-0921-5_2 · Cited by 163
Recent advances in biosensor technology in assessment of early diabetes biomarkers
Salek-Maghsoudi, A., Vakhshiteh, F., Torabi, R., Hassani, S., Ganjali, M. R., Norouzi, P., Hosseini, M., & Abdollahi, M. (2018) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2017.07.047 · Cited by 174
Partial pancreatectomy in adult humans does not provoke β-cell regeneration
Menge, B. A., Tannapfel, A., Belyaev, O., Drescher, R., Müller, C., Uhl, W., Schmidt, W. E., & Meier, J. J. (2008) · Diabetes · doi:10.2337/db07-1294 · Cited by 173
Cytokines in the Progression of Pancreatic β-Cell Dysfunction
Wang, C., Guan, Y., & Yang, J. (2010) · International Journal of Endocrinology · doi:10.1155/2010/515136 · Cited by 164
Anti‐inflammatory cytokines and risk of type 2 diabetes
Herder, C., Carstensen, M., & Ouwens, D. M. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12155 · Cited by 170
Reactive Oxygen Species and Oxidative Stress in the Pathogenesis of MAFLD
Clare, K., Dillon, J. F., & Brennan, P. N. (2022) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2022.00067 · Cited by 150
The Inflammasome in Atherosclerosis and Type 2 Diabetes
Masters, S. L., Latz, E., & O’Neill, L. A. J. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001902 · Cited by 169
Interleukin-1 and acute brain injury
Murray, K. N., Parry-Jones, A. R., & Allan, S. M. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00018 · Cited by 166
The unique hypusine modification of eIF5A promotes islet β cell inflammation and dysfunction in mice
Maier, B., Ogihara, T., Trace, A. P., Tersey, S. A., Robbins, R. D., Chakrabarti, S. K., Nunemaker, C. S., Stull, N. D., Taylor, C. A., Thompson, J. E., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci38924 · Cited by 166
“In the case of type 2 diabetes, systemic insulin resistance leads to increased circulating proinflammatory cytokines (3), and exogenous administration of IL-1 receptor antagonist (IL-1Ra) has been demonstrated to reduce glycemia and improve β cell function in mice with diet-induced hyperglycemia (4) and in human subje…”
BackgroundState of the union between metabolism and the immune system in type 2 diabetes
Nikolajczyk, B. S., Jagannathan-Bogdan, M., Shin, H., & Gyurko, R. (2011) · Genes & Immunity · doi:10.1038/gene.2011.14 · Cited by 166
Diabetes and inflammation: Fundamental aspects and clinical implications
Garcia, C., Feve, B., Ferré, P., Halimi, S., Baizri, H., Bordier, L., Guiu, G., Dupuy, O., Bauduceau, B., & Mayaudon, H. (2010) · Diabetes & Metabolism · doi:10.1016/j.diabet.2010.07.001 · Cited by 159
Thirty-One Novel Biomarkers as Predictors for Clinically Incident Diabetes
Salomaa, V., Havulinna, A., Saarela, O., Zeller, T., Jousilahti, P., Jula, A., Muenzel, T., Aromaa, A., Evans, A., Kuulasmaa, K., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010100 · Cited by 169
Adipokines as Drug Targets in Diabetes and Underlying Disturbances
Andrade-Oliveira, V., Câmara, N. O. S., & Moraes-Vieira, P. M. (2015) · Journal of Diabetes Research · doi:10.1155/2015/681612 · Cited by 166
“Indeed the administration of anti-TNF antibodies in mice resulted in reduced inflammation and the consequent protection against dietinduced obesity and insulin resistance [102, 103].”
Background
Metadata
- Authors
- Larsen, C. M., Faulenbach, M., Vaag, A., Vølund, A., Ehses, J. A., Seifert, B., Mandrup-Poulsen, T., & Donath, M. Y.
- Affiliations
- University Hospital Zurich (CH)
- Steno Diabetes Centers (DK)
- University of Zurich (CH)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-04-12
- Volume
- 356
- Issue
- 15
- Pages
- 1517-1526
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2024378513
- Cited by
- 1,798
- References
- 29
- Citations by year
- 2026: 41 · 2025: 47 · 2024: 61 · 2023: 75 · 2022: 89 · 2021: 97 · 2020: 84 · 2019: 83 · 2018: 87 · 2017: 77 · 2016: 111 · 2015: 113 · 2014: 135 · 2013: 141 · 2012: 132
- FWCI
- 93.91
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Lund University Publications (Lund University) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- anakinra, interleukin-1 receptor antagonist, type 2 diabetes, IL-1β, beta-cell function, insulin secretion, HbA1c, systemic inflammation, interleukin-6, C-reactive protein, C-peptide, hyperinsulinemic-euglycemic clamp, insulin resistance, adipokines
- MeSH terms
- Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha, Blood Glucose, C-Reactive Protein, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Gene Expression Regulation, Glucose Tolerance Test, Heat-Shock Proteins, Glycated Hemoglobin, Humans, Insulin Resistance, Male, Middle Aged, Recombinant Proteins, RNA, Messenger, Transcription Factors, Interleukin-6, Body Mass Index, Receptors, Interleukin-1, Insulin-Secreting Cells, Glucose Transporter Type 4, Interleukin 1 Receptor Antagonist Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.